One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC.

Firmonertinib shows promising systemic and intracranial efficacy in EGFR PACC-mutant non-small cell lung cancer (NSCLC), supporting further clinical development for this mutation class.

• Why it matters: EGFR PACC-mutant NSCLC has limited treatment options, and outcomes are challenging, especially when tumors are present in the brain.
• What they did: Le et al. generated preclinical profiles of the broad-spectrum CNS-penetrant tyrosine kinase inhibitor firmonertinib and evaluated its systemic and intracranial activity in this NSCLC mutation context.
• The result: The reported preclinical systemic and intracranial efficacy suggests firmonertinib may be a viable candidate for continued clinical testing in EGFR PACC-mutant NSCLC.

AI summary of the abstract · may contain errors · not medical advice · read the paper.